Brokerages Set Pediatrix Medical Group, Inc. (NYSE:MD) Price Target at $9.38

Shares of Pediatrix Medical Group, Inc. (NYSE:MD) have been assigned an average recommendation of “Hold” from the four analysts that are presently covering the company, Marketbeat.com reports. Four research analysts have rated the stock with a hold recommendation. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $9.38.

Several brokerages have recently issued reports on MD. Mizuho decreased their target price on Pediatrix Medical Group from $10.00 to $9.00 and set a “neutral” rating for the company in a research report on Wednesday, February 21st. TheStreet lowered Pediatrix Medical Group from a “c” rating to a “d” rating in a research report on Friday, February 23rd. Jefferies Financial Group decreased their target price on Pediatrix Medical Group from $10.00 to $9.00 and set a “hold” rating for the company in a research report on Wednesday, March 6th. Finally, Truist Financial reaffirmed a “hold” rating and set a $10.00 target price on shares of Pediatrix Medical Group in a research report on Wednesday, May 15th.

Institutional Trading of Pediatrix Medical Group

Institutional investors have recently made changes to their positions in the business. Pacer Advisors Inc. lifted its stake in shares of Pediatrix Medical Group by 126.9% in the 4th quarter. Pacer Advisors Inc. now owns 3,235,729 shares of the company’s stock valued at $30,092,000 after purchasing an additional 1,809,828 shares during the last quarter. Boston Partners bought a new stake in shares of Pediatrix Medical Group in the 4th quarter valued at approximately $12,452,000. Invenomic Capital Management LP lifted its stake in shares of Pediatrix Medical Group by 93.3% in the 4th quarter. Invenomic Capital Management LP now owns 1,377,951 shares of the company’s stock valued at $12,815,000 after purchasing an additional 664,955 shares during the last quarter. Clark Estates Inc. NY bought a new stake in shares of Pediatrix Medical Group in the 4th quarter valued at approximately $3,302,000. Finally, Envestnet Asset Management Inc. lifted its stake in shares of Pediatrix Medical Group by 250.6% during the 3rd quarter. Envestnet Asset Management Inc. now owns 267,434 shares of the company’s stock worth $3,399,000 after acquiring an additional 191,154 shares during the last quarter. Hedge funds and other institutional investors own 97.71% of the company’s stock.

Pediatrix Medical Group Stock Performance

NYSE:MD opened at $7.53 on Monday. The company has a market capitalization of $633.63 million, a PE ratio of -8.86, a P/E/G ratio of 1.42 and a beta of 1.58. The company has a 50 day simple moving average of $9.02 and a two-hundred day simple moving average of $9.16. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.72 and a current ratio of 1.72. Pediatrix Medical Group has a fifty-two week low of $7.26 and a fifty-two week high of $15.02.

Pediatrix Medical Group (NYSE:MD) last released its earnings results on Tuesday, February 20th. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.30 by $0.02. Pediatrix Medical Group had a negative net margin of 3.53% and a positive return on equity of 10.31%. The business had revenue of $496.44 million during the quarter, compared to the consensus estimate of $524.30 million. During the same quarter in the prior year, the firm posted $0.46 EPS. The company’s revenue for the quarter was down 3.4% compared to the same quarter last year. Research analysts anticipate that Pediatrix Medical Group will post 1.12 earnings per share for the current year.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.